Navigation Links
Neuralstem updates ALS clinical trial progress

ROCKVILLE, Maryland, October 18, 2010 Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first six non-ambulatory patients, the trial's Safety Monitoring Board has unanimously approved moving to the next group of ALS patients, all of whom will be ambulatory.

"We are pleased with the progress of the trial to date, and look forward to moving directly into more recently-diagnosed patients," commented Dr. Eva Feldman, PhD, MD, Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System.

"We are encouraged by the Board's approval to advance the trial to patients who have an earlier stage of the disease," said Neuralstem's CEO and president, Richard Garr. "While the primary endpoint of the trial is safety, we also hope to see some secondary endpoints showing efficacy. We are grateful to the patients, and their families, for participating in this trial."

The first six patients treated in the trial were non-ambulatory. Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord. The next three received ten injections each, bilaterally in the lumbar region. All of the remaining patients in the trial will be ambulatory, and therefore represent earlier stages of disease progression. Of the ambulatory group, the first three patients will receive five injections each, unilaterally, in the lumbar region. The next three will receive ten injections each, bilaterally, in the lumbar region. After the required FDA approval, the final six patients in the trial will receive injections in the cervical region, representing both a progression of treatment up the spinal cord, as well as into more recently-diagnosed patients.


Contact: Deanne Eagle
Neuralstem, Inc.

Related medicine news :

1. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
2. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
3. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
4. Neuralstem updates clinical trial progress
5. New "howsthepatient" iPhone App Provides a Simple, Seamless Way to Send Health Updates to Friends and Family
6. FDA Updates Import Alert 71-04 for Salmonella Contaminated Animal Feeds: Many Non-U.S. Firms Affected According to, LLC
7. Clone Systems, Inc. Updates PCI Solutions for Level 1 & 2 Merchants
8. American Traveler Offers New Healthcare Jobs Hourly, Updates Via Job RSS & Twitter
9. Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates
10. Sunquest Announces Major Software Updates and Enhancements
11. New clinical trial explores role of vitamin D in preventing esophageal cancer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Chiropractic ... University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester student in ... Carl S. Cleveland III on October 16. , “Katie is very excited and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... ... 2015 , ... Bibliomotion is thrilled to announce the launch of ... Diversity by Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health ... the needs of patients and their families, shaped my desire to improve the system ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Kevin Day, local family ... community stress less this holiday season. During the Indiana winter months, Vitamin D ... and the team at AlignLife want to help provide the tools needed to combat ...
(Date:11/24/2015)... ... November 24, 2015 , ... All her life, Don Peck’s mother wondered if she was a ... might have been. After a 25-year search for information, Don and his aunt discovered ... a last name. Turns out, it was Don’s father who was descended from not ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Boston Scientific Corporation (NYSE: BSX ... Annual Healthcare Conference on December 8, in ... , vice president, Investor Relations, will participate in a ... approximately 8:35 a.m. ET. --> Susie Lisa ... 30-minute question-and-answer session with the host analyst beginning at ...
(Date:11/24/2015)... Nov. 24, 2015  Enova Illumination is pleased to ... Helsinki, Finland to combine their world ... the cutting edge of medical visualization: Enova is the ... the United States and Novocam is the ... provide the world,s most powerful battery-operated LED headlight with ...
(Date:11/24/2015)... -based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ... production and dispensing of novel compounded pharmaceuticals.  The ... including ophthalmology, urology, sinus and integrative medicine.  Imprimis ... four facilities located in California ... New Jersey and Pennsylvania.  For more ...
Breaking Medicine Technology: